Braxia Scientific Corp.

CSE: BRAX, OTCQB: SHRMF

Company Logo

Company Overview

Braxia Scientific Corp., formerly Champignon Brands, is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. 

The company acquired ALTMed Capital Corp. in April 2020 to bolster its psychedelics presence with a fully operating ketamine clinic located in Ontario. The clinic has been licensed by Health Canada to dose eligible patients with psilocybin and is the only clinic in the country to perform psilocybin doses with the agency's approval.

Financial Highlights

$1,326,114

Revenue (ttm)

$145,666

Gross Profit (ttm)

-$0.04

Diluted EPS (ttm)

Management Team

Dr. Roger S. McIntyre
Chairman & CEO

Mr. Stephen R. Brooks
Chief Financial Officer

Dr. Joshua Rosenblat
Chief Medical & Scientific Officer

Mr. Peter Rizakos
Gen. Counsel

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$6,181,002

Shares Outstanding
79,258,993

Shares Short (% of Float)
()

Insider Ownership
15%